<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02586155</url>
  </required_header>
  <id_info>
    <org_study_id>RVX222-CS-015</org_study_id>
    <nct_id>NCT02586155</nct_id>
  </id_info>
  <brief_title>Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD</brief_title>
  <acronym>BETonMACE</acronym>
  <official_title>A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment With RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Resverlogix Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medidata Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Resverlogix Corp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether bromodomain extraterminal domain (BET)&#xD;
      inhibition treatment with RVX000222 in high-risk type 2 diabetes mellitus patients with&#xD;
      coronary artery disease increases the time to major adverse cardiovascular events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The majority (75%) of deaths in subjects with diabetes mellitus (DM) are due to&#xD;
      atherosclerotic cardiovascular disease (CVD). Recent studies suggest a major adverse&#xD;
      cardiovascular event (MACE) rate of &gt;11% over 18 months in type 2 diabetes mellitus (T2DM)&#xD;
      despite a baseline LDL-C of &lt;2.1 mmol/L. Bromodomains (BRDs) are a family of evolutionary&#xD;
      conserved protein-interaction modules that play key functions in chromatin organization and&#xD;
      regulation of gene transcription. One recognized family of bromodomain-containing proteins is&#xD;
      the bromodomain and extra-terminal (BET) family. BET inhibition represents a novel,&#xD;
      epigenetic approach to treat CAD.&#xD;
&#xD;
      RVX000222 affects biological processes important in atherosclerosis and acute coronary events&#xD;
      via selective inhibition of BET proteins. RVX000222 is available as a capsule formulation&#xD;
      with standard excipients and established stability.&#xD;
&#xD;
      The BETonMACE study will focus on prevention of subsequent MACE in subjects with CAD and DM&#xD;
      with high intensity statin therapy as co-medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">June 21, 2021</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of First Occurrence of Adjudication-confirmed Narrowly Defined MACE</measure>
    <time_frame>120 weeks</time_frame>
    <description>Incidence of first occurrence of MACE narrowly defined as a single composite endpoint of Cardiovascular (CV) Death (including undetermined cause of death) or Non-fatal Myocardial Infarction (MI) or Stroke. If a subject has multiple events, only the first event contributing to the composite endpoint is counted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of First Occurrence of Adjudication-confirmed Broadly Defined MACE</measure>
    <time_frame>120 weeks</time_frame>
    <description>First occurrence of MACE broadly defined as a single composite endpoint of Cardiovascular Death (CVD) (including undetermined cause of death) or Non-fatal Myocardial Infarction (MI), Stroke, or Hospitalization for CVD events (including unstable angina and evidence of new or presumed new progressive obstructive coronary disease or emergency revascularization procedures at any time and urgent revascularization procedures â‰¥30 days after the index event as defined by Hicks et al., 2014) . If a subject has multiple events, only the first event contributing to the composite endpoint is counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hospitalization for Congestive Heart Failure (CHF)</measure>
    <time_frame>120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of All-cause Mortality</measure>
    <time_frame>120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Apolipoprotein A1 (ApoA-I) Concentration From Baseline Over Time Within and Between Treatment Groups</measure>
    <time_frame>120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Apolipoprotein B (apoB) Concentration From Baseline Over Time Within and Between Treatment Groups</measure>
    <time_frame>120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL-C Concentration From Baseline Over Time Within and Between Treatment Groups</measure>
    <time_frame>120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL-C Concentration From Baseline Over Time Within and Between Treatment Groups</measure>
    <time_frame>120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglyceride (TG) Concentration From Baseline Over Time Within and Between Treatment Groups</measure>
    <time_frame>120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin (Hb) A1c From Baseline Over Time Within and Between Treatment Groups</measure>
    <time_frame>120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glucose From Baseline Over Time Between and Within Treatment Groups</measure>
    <time_frame>120 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alkaline Phosphatase (ALP) From Baseline Over Time Within and Between Treatment Groups</measure>
    <time_frame>172 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C Reactive Protein (CRP) Concentration From Baseline Over Time Within and Between Treatment Groups</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline Over Time Within and Between Treatment Groups for Subjects With Impaired Renal Function at Baseline (eGFR &lt;60 mL/Min/1.7m2)</measure>
    <time_frame>120 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2425</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>High-Intensity statin therapy+RVX000222</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Intensity statin therapy+Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apabetalone</intervention_name>
    <description>100 mg capsule</description>
    <arm_group_label>High-Intensity statin therapy+RVX000222</arm_group_label>
    <other_name>RVX000222</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule manufactured to mimic RVX000222 100 mg capsule</description>
    <arm_group_label>High-Intensity statin therapy+Placebo</arm_group_label>
    <other_name>Placebo (for RVX000222)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>High-Intensity Statin</description>
    <arm_group_label>High-Intensity statin therapy+Placebo</arm_group_label>
    <arm_group_label>High-Intensity statin therapy+RVX000222</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>High-Intensity Statin</description>
    <arm_group_label>High-Intensity statin therapy+Placebo</arm_group_label>
    <arm_group_label>High-Intensity statin therapy+RVX000222</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ ACS event of either unstable angina or myocardial infarction 7-90 days prior Visit 1:&#xD;
&#xD;
        Unstable angina: for a qualifying unstable angina event, each of components (a), (b), and&#xD;
        (c) must be satisfied: a.) Characteristic ischemic pain or discomfort in chest/associated&#xD;
        referral areas, occurring at rest/with minimal exertion b.) ECG changes consistent with&#xD;
        acute myocardial ischemia based on new/presumed ST elevation/depression or T-wave inversion&#xD;
        c.) Objective evidence of obstructive CAD based on 1+ of the following: i. New/presumed new&#xD;
        evidence of myocardial ischemia/infarction by perfusion imaging ii. New/presumed new&#xD;
        regional wall motion abnormality iii. Current evidence of at least 1 epicardial coronary&#xD;
        artery stenosis â‰¥70% by coronary angiography iv. Need for coronary revascularization for&#xD;
        the index ACS event, including a percutaneous coronary intervention (PCI) with or without&#xD;
        coronary stenting.&#xD;
&#xD;
        Prior MI 7-90 days prior screening treated with or without a percutaneous coronary&#xD;
        intervention (PCI). For a qualifying event of MI 2 of the following 3 criteria must be&#xD;
        satisfied: a.) Characteristic ischemic chest pain/pain in associated referral areas b.)&#xD;
        Dynamic elevation of troponin T/I or CKMB if troponinT/I is unavailable at local lab (at&#xD;
        least &gt;ULN for lab) c.) Development of new Q-waves in â‰¥2 adjacent ECG leads or development&#xD;
        of new dominant R wave in V1&#xD;
&#xD;
          -  Documented diagnosis of T2DM (1+ of the following criteria): Documented history of&#xD;
             T2DM, History of taking diabetes medication, and/or HbA1c â‰¥6.5% at Visit 1&#xD;
&#xD;
          -  For males HDL-C&lt;40 mg/dL(1.04 mmol/L), for females HDL-C&lt;45 mg/dL(1.17 mmol/L) at&#xD;
             Visit 1&#xD;
&#xD;
          -  Subjects currently not on high intensity statin therapy could start rosuvastatin at&#xD;
             Visit 1 and those currently on therapy besides atorvastatin/rosuvastatin can be&#xD;
             switched to rosuvastatin at Visit 1&#xD;
&#xD;
          -  Female subjects of non-childbearing potential (post-surgical&#xD;
             sterilization/post-menopausal) or if childbearing potential have neg urine pregnancy&#xD;
             test and be willing and able to use non-hormonal birth control (non-hormonal IUD,&#xD;
             condom or diaphragm) or remain abstinent from Screening to Follow-up Visit&#xD;
&#xD;
          -  Give signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Heart disease which will w/in 90 days of Visit 1 likely need coronary bypass, PCI,&#xD;
             cardiac transplantation, surgical repair and/or replacement&#xD;
&#xD;
          -  Previous/current diagnosis of severe heart failure or documented LVEF&lt;25% determined&#xD;
             by contrast left ventriculography, radionuclide ventriculography or echocardiography.&#xD;
             Absence of LVEF measurement in subject w/out a previous/current diagnosis of heart&#xD;
             failure does not exclude entry into study&#xD;
&#xD;
          -  Evidence of cardiac EP instability incl. history of uncontrolled ventricular&#xD;
             arrhythmias, atrial fibrillation/flutter or supraventricular tachycardias w/ a&#xD;
             ventricular response HR&gt;100bpm at rest w/in 4 wks prior Visit 1&#xD;
&#xD;
          -  CABG w/in 90 days prior Visit 1&#xD;
&#xD;
          -  Evidence of severe renal impairment as determined by either eGFR&lt;30 mL/min/1.7m2 at&#xD;
             Visit 1 or current need for dialysis&#xD;
&#xD;
          -  Uncontrolled hypertension defined as 2 consecutive measurements of sitting BP of&#xD;
             systolic&gt;180 mmHg or diastolic&gt;100 mmHg at Visit 1&#xD;
&#xD;
          -  Treatment w/ immunosuppressants w/in 12 mos prior Visit 1&#xD;
&#xD;
          -  Use of fibrates at any dose or niacin/nicotinic acid 250+ mg w/in 30 days prior Visit&#xD;
             1&#xD;
&#xD;
          -  Known allergy/sensitivity to any ingredient in IMP&#xD;
&#xD;
          -  History of intolerance to atorvastatin/rosuvastatin&#xD;
&#xD;
          -  Triglycerides&gt;400 mg/dL (4.52 mmol/L) at Visit 1&#xD;
&#xD;
          -  Any medical/surgical condition which might significantly alter absorption,&#xD;
             distribution, metabolism or excretion of medication&#xD;
&#xD;
          -  Evidence of cirrhosis from liver imaging/biopsy, history of hepatic encephalopathy,&#xD;
             esophageal/gastric varices, active hepatitis or prior porta-caval shunt procedure or a&#xD;
             Child-Pugh score of â‰¥5 points&#xD;
&#xD;
          -  ALT/AST&gt;1.5xULN by central lab at Visit 1&#xD;
&#xD;
          -  Tot. bilirubin&gt;ULN by central lab at Visit 1&#xD;
&#xD;
          -  History of malignancy of any organ syst treated/untreated w/in the past 2 yrs whether&#xD;
             or not there is evidence of local recurrence/metastases except localized basal skin&#xD;
             cell carcinoma&#xD;
&#xD;
          -  History/evidence of drug/alcohol abuse w/in 12 mos of Visit 1&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Any condition which may place subject at higher risk from his/her participation in the&#xD;
             study or is likely to prevent subject from completing/complying w/ requirements of&#xD;
             study&#xD;
&#xD;
          -  Use of other investigational drugs and devices w/in 30 days or 5 half-lives of Visit&#xD;
             1, whichever is longer&#xD;
&#xD;
          -  History of noncompliance to medical regimens or unwillingness to comply w/ study&#xD;
             protocol&#xD;
&#xD;
          -  Any condition that would confound the evaluation/interpretation of efficacy and/or&#xD;
             safety data&#xD;
&#xD;
          -  Persons directly involved in execution of this protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kausik Ray, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas Bahia Blanca</name>
      <address>
        <city>BahÃ­a Blanca</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinica Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Privado de Enfermedades Cardiovasculares</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorios Asociados EndocronologÃ­a E InvestigaciÃ³n ClÃ­nica Aplicada</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Cardiovascular de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Guemes</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Coronel Suarez</name>
      <address>
        <city>Coronel SuÃ¡rez</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiologia de Corrientes Juana Francisca Cabral</name>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEMAIC</name>
      <address>
        <city>CÃ³rdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro MÃ©dico ColÃ³n</name>
      <address>
        <city>CÃ³rdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro MÃ©dico Luquez</name>
      <address>
        <city>CÃ³rdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClÃ­nica Privada Del Prado Sociedad de Responsabilidad Limitada</name>
      <address>
        <city>CÃ³rdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FundaciÃ³n ClÃ­nica Colombo</name>
      <address>
        <city>CÃ³rdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cordoba</name>
      <address>
        <city>CÃ³rdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Roque</name>
      <address>
        <city>CÃ³rdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Del CorazÃ³n</name>
      <address>
        <city>CÃ³rdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Modelo de Cardiologia</name>
      <address>
        <city>CÃ³rdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto MÃ©dico DAMIC</name>
      <address>
        <city>CÃ³rdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ipac Caraffa</name>
      <address>
        <city>CÃ³rdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Allende</name>
      <address>
        <city>CÃ³rdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro MÃ©dico Libertad</name>
      <address>
        <city>Haedo</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIMEL</name>
      <address>
        <city>LanÃºs</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones ClÃ­nicas Mar Del Plata</name>
      <address>
        <city>Mar Del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIM Clinica Privada</name>
      <address>
        <city>Ramos Mejia</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Hematologia Y Medicina Clinica</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Britanico de Rosario</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prevencion Cardio Vascular</name>
      <address>
        <city>Salta</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grupo Medico Alem</name>
      <address>
        <city>San Isidro</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinica TucumÃ¡n</name>
      <address>
        <city>San Miguel De TucumÃ¡n</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Modelo de Cardiologia</name>
      <address>
        <city>San Miguel De TucumÃ¡n</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigaciones Clinicas Tucuman</name>
      <address>
        <city>San Miguel De TucumÃ¡n</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones ClÃ­nicas Del Litoral SRL</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio San Francisco</name>
      <address>
        <city>Santiago Del Estero</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClÃ­nica FUSAVIM Privada</name>
      <address>
        <city>Villa MarÃ­a</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones ClÃ­nicas ZÃ¡rate</name>
      <address>
        <city>ZÃ¡rate</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda VZW</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital For Active Treatment Dr Tota Venkova</name>
      <address>
        <city>Gabrovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Prof. Dr. Paraskev Stoyanov AD</name>
      <address>
        <city>Lovech</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital For Active Treatment - Pazardzhik AD</name>
      <address>
        <city>Pazardzhik</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski EAD</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital For Active Treatment - Dr. Bratan Shukerov AD</name>
      <address>
        <city>Smolyan</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinic University Multiprofile Hospital for Active Treatment EOOD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Kardiohelp EOOD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Multiprofile Hospital for Active Treatment Sofia</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Affiliate - Diagnostic and Consulting Center Ascendent</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Aleksandrovska EAD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment and Emergency Medicine N. I. Pirogov EAD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Orfey OOD</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Sveta Marina EAD</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Karlovac</name>
      <address>
        <city>Karlovac</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Special Hospital for medicinal rehabilitation Krapinske Toplice</name>
      <address>
        <city>Krapinske Toplice</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Osijek</name>
      <address>
        <city>Osijek</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Dr Josip Bencevic</name>
      <address>
        <city>Slavonski Brod</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Virovitica</name>
      <address>
        <city>Virovitica</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Sveti duh</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRK Kliniken Berlin Westend</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum am KÃ¼chwald GmbH</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum fÃ¼r Klinische PrÃ¼fung in der Facharztzentrum Dresden Neustadt Gbr</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Krankenhaus St. Johann Nepomuk</name>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heidelberger Praxisklinik fÃ¼r Kardiologie</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Hoyerswerda</name>
      <address>
        <city>Hoyerswerda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Dr.Appel</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Langen</name>
      <address>
        <city>Langen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Leverkusen GmbH</name>
      <address>
        <city>Leverkusen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bajai Szent RÃ³kus KÃ³rhÃ¡z</name>
      <address>
        <city>Baja</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grof Tisza Istvan Korhaz Berettyoujfalu</name>
      <address>
        <city>BerettyÃ³Ãºjfalu</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bajcsy-Zsilinszky Korhaz es Rendelointezet</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Del-pesti Centrumkorhaz- Orszagos Hematologiai Ã©s Infektologiai Intezet</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottsegen Gyorgy Orszagos Kardiologiai Intezet</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar HonvÃ©dsÃ©g EgÃ©szsÃ©gÃ¼gyi KÃ¶zpont</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus (DRS) - Synexus MagyarorszÃ¡g Kft. Budapest</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Margit Korhaz</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent RÃ³kus KÃ³rhÃ¡z Ã©s IntÃ©zmÃ©nyei</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Selye JÃ¡nos KÃ³rhÃ¡z</name>
      <address>
        <city>KomÃ¡rom</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TaNaMed Kft.</name>
      <address>
        <city>MosonmagyarÃ³vÃ¡r</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanizsai Dorottya KÃ³rhÃ¡z</name>
      <address>
        <city>Nagykanizsa</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coromed-SMO Kft.</name>
      <address>
        <city>PÃ©cs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tolna Megyei Balassa JÃ¡nos KÃ³rhÃ¡z</name>
      <address>
        <city>SzekszÃ¡rd</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz</name>
      <address>
        <city>SzÃ©kesfehÃ©rvÃ¡r</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Centre</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnei Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lady Davis Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linn Medical Center Clalit Health Services</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edith Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital Ein Kerem</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital Mount Scopus</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kefar-Sava</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galilee Medical Center</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nazareth EMMS Hospital</name>
      <address>
        <city>Nazareth</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZIV Medical Center</name>
      <address>
        <city>Safed</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clalit Health Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baruch Padeh Poriya Medical Center</name>
      <address>
        <city>Tiberias</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardiovascular de Aguascalientes AC</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital CardiolÃ³gica Aguascalientes</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigacion en Salud y Metabolismo S.C.</name>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de InvestigaciÃ³n Biomedica y Farmaceutica</name>
      <address>
        <city>Ciudad de MÃ©xico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Integral del Paciente Diabetico y Obeso</name>
      <address>
        <city>Ciudad De MÃ©xico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FundaciÃ³n de AtenciÃ³n e InvestigaciÃ³n MÃ©dica Lindavista S.C.</name>
      <address>
        <city>Ciudad de MÃ©xico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Para el Desarrollo de la Medicina y de Asistencia Especializada SC</name>
      <address>
        <city>Culiacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion y Atencion de Diabetes, Endocrinologia y Nutricion</name>
      <address>
        <city>Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arechavaleta Granell Maria del Rosario</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Medica Biologica Y de Terapia Avanzada SC</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigacion Clinica Cardiometabolica de Occidente SC</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Angeles Leon</name>
      <address>
        <city>LeÃ³n De Los Aldama</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Desarrollo BiomÃ©dico</name>
      <address>
        <city>Merida</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio y Servicios MÃ©dicos ObregÃ³n S.A. de C.V.</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Cardiovascular de Monclova</name>
      <address>
        <city>Monclova</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose Eleuterio GonzÃ¡lez</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMED Internal Medicine Clin Trials</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de InvestigaciÃ³n ClÃ­nica En Medicina SC</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Total, S.A de C.V.</name>
      <address>
        <city>Pachuca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigacion Biomedica Aplicada de Hidalgo S.A. de C.V.</name>
      <address>
        <city>Pachuca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardioarritmias e InvestigaciÃ³n S.C.</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central Dr Ignacio Morones Prieto</name>
      <address>
        <city>San Luis PotosÃ­</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INBIOMEDYC Toluca</name>
      <address>
        <city>Toluca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Alta Especialidad Dr. Rafael Lucio</name>
      <address>
        <city>Veracruz</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Humberto Alvarez Lopez</name>
      <address>
        <city>Zapopan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLVG locatie Oost</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Podlaski Osrodek Kardiologii Poradnia Prywatna</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Sercowo-Naczyniowe</name>
      <address>
        <city>Chrzanow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polsko-Amerykanskie Kliniki Serca</name>
      <address>
        <city>Dabrowa Gornicza</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Kardiologiczno-Internistyczny</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej Centrum Uslug Medycznych Promont-Med.</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diamond Clinic</name>
      <address>
        <city>KrakÃ³w</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny im. Jozefa Dietla w Krakowie</name>
      <address>
        <city>KrakÃ³w</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zespol Przychodni Specjalistycznych DIAB-END-COR Sp. z o.o.</name>
      <address>
        <city>KrakÃ³w</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatna Praktyka Lekarska MAZ-MEDICA Maciej R.Mazurkiewicz</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny im. Wojskowej Akademii Medycznej Centralny Szpital Weteranow</name>
      <address>
        <city>LÃ³dz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polsko-Amerykanskie Kliniki Serca</name>
      <address>
        <city>Nysa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pro Corde, Dom Medyczny</name>
      <address>
        <city>Opole</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicome Sp. z o.o.</name>
      <address>
        <city>Oswiecim</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rodzinne Centrum Zdrowia</name>
      <address>
        <city>Otwock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej Specjalistyczna Przychodnia Lekarska &quot;MEDIKARD&quot;</name>
      <address>
        <city>Plock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej Centrum Medyczne SBB</name>
      <address>
        <city>Tarnobrzeg</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne doktorA</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Kardiologii im Prymasa Tysiaclecia Kardynala Stefana Wyszynskiego</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej AURUM</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Kardiologiczne Pro Corde Sp. z o.o. Niepubliczny Zaklad Opieki Zdrowotnej</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wro Medica</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #6</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ural State Medical University</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Budget Healthcare Institution Medici - sanitary unit of Ministry of internal affairs of Russ</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Complex Cardiovascular Pathology</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnodar Regional Clinical Hospital #2</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City State Budgetary Healthcare Institution City Clinical Hospital named after V.V. Veresayev</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Cardiology Research and Production Center</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital 13</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Novosibirsk Region City Clinical Hospital No. 19</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Hospital n.a. V.A. Baranov</name>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Budgetary Healthcare Institution City Emergency Hospital</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Medical Center SOGAZ</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North-West State Medical University n.a. I.I. Mechnikov</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Petersburg City Outpatient Clinic #109</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution Regional Clinical Cardiologic Dispensary</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #4</name>
      <address>
        <city>Sochi</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Cardiology Institute of Tomsk Scientific Center of RAMS Siberian Branch</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Vladimir Region City Hospital No. 4</name>
      <address>
        <city>Vladimir</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centar Zvezdara</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Bezanijska Kosa</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre Zemun</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Euromedik</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiovascular Diseases Dedinje</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KBC Dr Dragisa Misovic Dedinje</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Niska Banja</name>
      <address>
        <city>Niska Banja</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Nis</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Vojvodina</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiovascular Diseases of Vojvodina</name>
      <address>
        <city>Sremska Kamenica</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Uzice</name>
      <address>
        <city>Uzice</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Center Zajecar</name>
      <address>
        <city>Zajecar</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALIAN, s.r.o</name>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARDIOCONSULT, s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Bratislava</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardio-Onkologia, s.r.o.</name>
      <address>
        <city>Dolny Kubin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARDIO D&amp;R, s.r.o. Kosice</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zeleznicne zdravotnictvo Kosice, s.r.o.</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KARDIOMED s.r.o.</name>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDI M&amp;M s.r.o.</name>
      <address>
        <city>Moldava nad Bodvou</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnica s poliklinikou Nove Mesto nad Vahom n.o.</name>
      <address>
        <city>Nove Mesto nad Vahom</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardioinvest s. r. o.</name>
      <address>
        <city>Nove Zamky</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIAB s.r.o.</name>
      <address>
        <city>Roznava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDIVASA, s.r.o.</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital-Taipei branch</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cathay General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation Linkou Branch (Clinical Research Center)</name>
      <address>
        <city>Taoyuan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://jamanetwork.com/journals/jama/fullarticle/2763951</url>
    <description>Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes A Randomized Clinical Trial</description>
  </link>
  <results_reference>
    <citation>Ray KK, Nicholls SJ, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Sweeney M, Schwartz GG; BETonMACE Investigators and Committees. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2020 Apr 28;323(16):1565-1573. doi: 10.1001/jama.2020.3308.</citation>
    <PMID>32219359</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 21, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <results_first_submitted>June 21, 2021</results_first_submitted>
  <results_first_submitted_qc>July 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2021</results_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT02586155/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT02586155/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High-Intensity Statin Therapy+RVX000222</title>
          <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
        </group>
        <group group_id="P2">
          <title>High-Intensity Statin Therapy+Placebo</title>
          <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1215"/>
                <participants group_id="P2" count="1210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Final Number Randomized</title>
              <participants_list>
                <participants group_id="P1" count="1212"/>
                <participants group_id="P2" count="1206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1088"/>
                <participants group_id="P2" count="1083"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="127"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of the initial 1215 participants randomized into the High-Intensity statin therapy+RVX000222 group, 3 were randomized in error. Of the initial 1210 participants randomized into the High-Intensity statin therapy+placebo group, 4 were randomized in error.</population>
      <group_list>
        <group group_id="B1">
          <title>High-Intensity Statin Therapy+RVX000222</title>
          <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
        </group>
        <group group_id="B2">
          <title>High-Intensity Statin Therapy+Placebo</title>
          <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1212"/>
            <count group_id="B2" value="1206"/>
            <count group_id="B3" value="2418"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1212"/>
                    <count group_id="B2" value="1206"/>
                    <count group_id="B3" value="2418"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.0" lower_limit="33.0" upper_limit="85.0"/>
                    <measurement group_id="B2" value="62.0" lower_limit="31.0" upper_limit="88.0"/>
                    <measurement group_id="B3" value="62.0" lower_limit="31.0" upper_limit="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>â‰¤65 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1212"/>
                    <count group_id="B2" value="1206"/>
                    <count group_id="B3" value="2418"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="816"/>
                    <measurement group_id="B2" value="772"/>
                    <measurement group_id="B3" value="1588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1212"/>
                    <count group_id="B2" value="1206"/>
                    <count group_id="B3" value="2418"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="396"/>
                    <measurement group_id="B2" value="434"/>
                    <measurement group_id="B3" value="830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1212"/>
                    <count group_id="B2" value="1206"/>
                    <count group_id="B3" value="2418"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="305"/>
                    <measurement group_id="B2" value="313"/>
                    <measurement group_id="B3" value="618"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="907"/>
                    <measurement group_id="B2" value="893"/>
                    <measurement group_id="B3" value="1800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1212"/>
                    <count group_id="B2" value="1206"/>
                    <count group_id="B3" value="2418"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1063"/>
                    <measurement group_id="B2" value="1056"/>
                    <measurement group_id="B3" value="2119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <population>Body weight data is missing for some subjects</population>
          <units>kilograms (kg)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1210"/>
                    <count group_id="B2" value="1206"/>
                    <count group_id="B3" value="2416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.75" lower_limit="47.5" upper_limit="162.0"/>
                    <measurement group_id="B2" value="85.90" lower_limit="43.6" upper_limit="160.0"/>
                    <measurement group_id="B3" value="85.90" lower_limit="43.6" upper_limit="162.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body-mass index (BMI)</title>
          <population>Body-mass index (BMI) data missing for some subjects</population>
          <units>kg/m2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1208"/>
                    <count group_id="B2" value="1206"/>
                    <count group_id="B3" value="2414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.589" lower_limit="20.04" upper_limit="53.46"/>
                    <measurement group_id="B2" value="29.585" lower_limit="18.33" upper_limit="51.17"/>
                    <measurement group_id="B3" value="29.585" lower_limit="18.33" upper_limit="53.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of First Occurrence of Adjudication-confirmed Narrowly Defined MACE</title>
        <description>Incidence of first occurrence of MACE narrowly defined as a single composite endpoint of Cardiovascular (CV) Death (including undetermined cause of death) or Non-fatal Myocardial Infarction (MI) or Stroke. If a subject has multiple events, only the first event contributing to the composite endpoint is counted.</description>
        <time_frame>120 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-Intensity Statin Therapy+RVX000222</title>
            <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
          <group group_id="O2">
            <title>High-Intensity Statin Therapy+Placebo</title>
            <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of First Occurrence of Adjudication-confirmed Narrowly Defined MACE</title>
          <description>Incidence of first occurrence of MACE narrowly defined as a single composite endpoint of Cardiovascular (CV) Death (including undetermined cause of death) or Non-fatal Myocardial Infarction (MI) or Stroke. If a subject has multiple events, only the first event contributing to the composite endpoint is counted.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CV Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-fatal MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1070</p_value>
            <method>Stratified long-rank</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.823</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.649</ci_lower_limit>
            <ci_upper_limit>1.044</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of First Occurrence of Adjudication-confirmed Broadly Defined MACE</title>
        <description>First occurrence of MACE broadly defined as a single composite endpoint of Cardiovascular Death (CVD) (including undetermined cause of death) or Non-fatal Myocardial Infarction (MI), Stroke, or Hospitalization for CVD events (including unstable angina and evidence of new or presumed new progressive obstructive coronary disease or emergency revascularization procedures at any time and urgent revascularization procedures â‰¥30 days after the index event as defined by Hicks et al., 2014) . If a subject has multiple events, only the first event contributing to the composite endpoint is counted.</description>
        <time_frame>120 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-Intensity Statin Therapy+RVX000222</title>
            <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
          <group group_id="O2">
            <title>High-Intensity Statin Therapy+Placebo</title>
            <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of First Occurrence of Adjudication-confirmed Broadly Defined MACE</title>
          <description>First occurrence of MACE broadly defined as a single composite endpoint of Cardiovascular Death (CVD) (including undetermined cause of death) or Non-fatal Myocardial Infarction (MI), Stroke, or Hospitalization for CVD events (including unstable angina and evidence of new or presumed new progressive obstructive coronary disease or emergency revascularization procedures at any time and urgent revascularization procedures â‰¥30 days after the index event as defined by Hicks et al., 2014) . If a subject has multiple events, only the first event contributing to the composite endpoint is counted.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CV Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-fatal MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization for CVD events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1495</p_value>
            <method>Stratified long-rank</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.849</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.679</ci_lower_limit>
            <ci_upper_limit>1.061</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hospitalization for Congestive Heart Failure (CHF)</title>
        <time_frame>120 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-Intensity Statin Therapy+RVX000222</title>
            <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
          <group group_id="O2">
            <title>High-Intensity Statin Therapy+Placebo</title>
            <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hospitalization for Congestive Heart Failure (CHF)</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Stratified long-rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of All-cause Mortality</title>
        <time_frame>120 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-Intensity Statin Therapy+RVX000222</title>
            <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
          <group group_id="O2">
            <title>High-Intensity Statin Therapy+Placebo</title>
            <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>Stratified long-rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Apolipoprotein A1 (ApoA-I) Concentration From Baseline Over Time Within and Between Treatment Groups</title>
        <time_frame>120 weeks</time_frame>
        <population>A select subset of subjects were analyzed for ApoA-I, Subject data is missing across time points.</population>
        <group_list>
          <group group_id="O1">
            <title>High-Intensity Statin Therapy+RVX000222</title>
            <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
          <group group_id="O2">
            <title>High-Intensity Statin Therapy+Placebo</title>
            <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Apolipoprotein A1 (ApoA-I) Concentration From Baseline Over Time Within and Between Treatment Groups</title>
          <population>A select subset of subjects were analyzed for ApoA-I, Subject data is missing across time points.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="238"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.0" lower_limit="110.0" upper_limit="130.0"/>
                    <measurement group_id="O2" value="117.5" lower_limit="108.0" upper_limit="128.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Week 24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.0" lower_limit="118.5" upper_limit="138.5"/>
                    <measurement group_id="O2" value="125.0" lower_limit="114.0" upper_limit="138.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="207"/>
                    <count group_id="O2" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.0" lower_limit="118.0" upper_limit="141.0"/>
                    <measurement group_id="O2" value="124.0" lower_limit="114.0" upper_limit="136.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 16 (Week 76)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.0" lower_limit="119.0" upper_limit="146.0"/>
                    <measurement group_id="O2" value="125.0" lower_limit="112.0" upper_limit="136.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 18 (Week 100)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.0" lower_limit="119.0" upper_limit="142.5"/>
                    <measurement group_id="O2" value="125.0" lower_limit="115.0" upper_limit="138.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Visit on Treatment (LVT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.5" lower_limit="120.0" upper_limit="147.0"/>
                    <measurement group_id="O2" value="129.0" lower_limit="115.5" upper_limit="141.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.0" lower_limit="119.0" upper_limit="146.0"/>
                    <measurement group_id="O2" value="127.0" lower_limit="116.0" upper_limit="143.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Apolipoprotein B (apoB) Concentration From Baseline Over Time Within and Between Treatment Groups</title>
        <time_frame>120 weeks</time_frame>
        <population>A select subset of subjects were analyzed for ApoB, Subject data is missing across time points.</population>
        <group_list>
          <group group_id="O1">
            <title>High-Intensity Statin Therapy+RVX000222</title>
            <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
          <group group_id="O2">
            <title>High-Intensity Statin Therapy+Placebo</title>
            <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Apolipoprotein B (apoB) Concentration From Baseline Over Time Within and Between Treatment Groups</title>
          <population>A select subset of subjects were analyzed for ApoB, Subject data is missing across time points.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="238"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" lower_limit="54.0" upper_limit="80.0"/>
                    <measurement group_id="O2" value="66.0" lower_limit="53.0" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Week 24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" lower_limit="55.0" upper_limit="80.5"/>
                    <measurement group_id="O2" value="68.0" lower_limit="53.0" upper_limit="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="207"/>
                    <count group_id="O2" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="59.0" upper_limit="84.0"/>
                    <measurement group_id="O2" value="68.0" lower_limit="56.0" upper_limit="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 16 (Week 76)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" lower_limit="58.0" upper_limit="87.0"/>
                    <measurement group_id="O2" value="69.0" lower_limit="55.0" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 18 (Week 100)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" lower_limit="59.0" upper_limit="85.0"/>
                    <measurement group_id="O2" value="72.0" lower_limit="58.0" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Visit on Treatment (LVT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="56.0" upper_limit="85.0"/>
                    <measurement group_id="O2" value="72.0" lower_limit="57.5" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="57.0" upper_limit="86.0"/>
                    <measurement group_id="O2" value="71.0" lower_limit="57.0" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LDL-C Concentration From Baseline Over Time Within and Between Treatment Groups</title>
        <time_frame>120 weeks</time_frame>
        <population>All subjects were analyzed and contributed LDL-C data for the 'High-Intensity Statin Therapy + RVX000222' and the 'High-Intensity statin therapy + Placebo' arms.&#xD;
Subject data is missing across time points.</population>
        <group_list>
          <group group_id="O1">
            <title>High-Intensity Statin Therapy+RVX000222</title>
            <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
          <group group_id="O2">
            <title>High-Intensity Statin Therapy+Placebo</title>
            <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL-C Concentration From Baseline Over Time Within and Between Treatment Groups</title>
          <population>All subjects were analyzed and contributed LDL-C data for the 'High-Intensity Statin Therapy + RVX000222' and the 'High-Intensity statin therapy + Placebo' arms.&#xD;
Subject data is missing across time points.</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1140"/>
                    <count group_id="O2" value="1130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.690" lower_limit="1.270" upper_limit="2.215"/>
                    <measurement group_id="O2" value="1.690" lower_limit="1.260" upper_limit="2.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Week 24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1005"/>
                    <count group_id="O2" value="1007"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.530" lower_limit="1.160" upper_limit="2.010"/>
                    <measurement group_id="O2" value="1.530" lower_limit="1.140" upper_limit="1.970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="979"/>
                    <count group_id="O2" value="986"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.590" lower_limit="1.210" upper_limit="2.120"/>
                    <measurement group_id="O2" value="1.655" lower_limit="1.240" upper_limit="2.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 16 Week 76)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="785"/>
                    <count group_id="O2" value="799"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.600" lower_limit="1.230" upper_limit="2.090"/>
                    <measurement group_id="O2" value="1.660" lower_limit="1.270" upper_limit="2.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 18 Week 100)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="553"/>
                    <count group_id="O2" value="560"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.660" lower_limit="1.300" upper_limit="2.180"/>
                    <measurement group_id="O2" value="1.725" lower_limit="1.300" upper_limit="2.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Visit on Treatment (LVT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="864"/>
                    <count group_id="O2" value="898"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.700" lower_limit="1.240" upper_limit="2.240"/>
                    <measurement group_id="O2" value="1.745" lower_limit="1.290" upper_limit="2.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="817"/>
                    <count group_id="O2" value="839"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.650" lower_limit="1.250" upper_limit="2.210"/>
                    <measurement group_id="O2" value="1.680" lower_limit="1.240" upper_limit="2.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HDL-C Concentration From Baseline Over Time Within and Between Treatment Groups</title>
        <time_frame>120 weeks</time_frame>
        <population>All subjects were analyzed and contributed HDL-C data for the 'High-Intensity Statin Therapy + RVX000222' and the 'High-Intensity statin therapy + Placebo' arms.&#xD;
Subject data is missing across time points.</population>
        <group_list>
          <group group_id="O1">
            <title>High-Intensity Statin Therapy+RVX000222</title>
            <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
          <group group_id="O2">
            <title>High-Intensity Statin Therapy+Placebo</title>
            <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HDL-C Concentration From Baseline Over Time Within and Between Treatment Groups</title>
          <population>All subjects were analyzed and contributed HDL-C data for the 'High-Intensity Statin Therapy + RVX000222' and the 'High-Intensity statin therapy + Placebo' arms.&#xD;
Subject data is missing across time points.</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1140"/>
                    <count group_id="O2" value="1133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.870" lower_limit="0.770" upper_limit="0.960"/>
                    <measurement group_id="O2" value="0.860" lower_limit="0.780" upper_limit="0.960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Week 24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1005"/>
                    <count group_id="O2" value="1007"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.970" lower_limit="0.840" upper_limit="1.100"/>
                    <measurement group_id="O2" value="0.940" lower_limit="0.810" upper_limit="1.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="979"/>
                    <count group_id="O2" value="986"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.970" lower_limit="0.840" upper_limit="1.110"/>
                    <measurement group_id="O2" value="0.930" lower_limit="0.820" upper_limit="1.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 16 Week 76)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="787"/>
                    <count group_id="O2" value="800"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.960" lower_limit="0.830" upper_limit="1.110"/>
                    <measurement group_id="O2" value="0.920" lower_limit="0.800" upper_limit="1.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 18 Week 100)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1212"/>
                    <count group_id="O2" value="1206"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.970" lower_limit="0.840" upper_limit="1.110"/>
                    <measurement group_id="O2" value="0.910" lower_limit="0.810" upper_limit="1.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Visit on Treatment (LVT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="860"/>
                    <count group_id="O2" value="892"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.990" lower_limit="0.870" upper_limit="1.145"/>
                    <measurement group_id="O2" value="0.960" lower_limit="0.830" upper_limit="1.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="804"/>
                    <count group_id="O2" value="823"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.010" lower_limit="0.870" upper_limit="1.150"/>
                    <measurement group_id="O2" value="0.950" lower_limit="0.850" upper_limit="1.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglyceride (TG) Concentration From Baseline Over Time Within and Between Treatment Groups</title>
        <time_frame>120 weeks</time_frame>
        <population>All subjects were analyzed and contributed TG data for the 'High-Intensity Statin Therapy + RVX000222' and the 'High-Intensity statin therapy + Placebo' arms.&#xD;
Subject data is missing across time points.</population>
        <group_list>
          <group group_id="O1">
            <title>High-Intensity Statin Therapy+RVX000222</title>
            <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
          <group group_id="O2">
            <title>High-Intensity Statin Therapy+Placebo</title>
            <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglyceride (TG) Concentration From Baseline Over Time Within and Between Treatment Groups</title>
          <population>All subjects were analyzed and contributed TG data for the 'High-Intensity Statin Therapy + RVX000222' and the 'High-Intensity statin therapy + Placebo' arms.&#xD;
Subject data is missing across time points.</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1140"/>
                    <count group_id="O2" value="1132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.630" lower_limit="1.245" upper_limit="2.205"/>
                    <measurement group_id="O2" value="1.690" lower_limit="1.310" upper_limit="2.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Week 24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1005"/>
                    <count group_id="O2" value="1007"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.660" lower_limit="1.260" upper_limit="2.260"/>
                    <measurement group_id="O2" value="1.670" lower_limit="1.200" upper_limit="2.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="980"/>
                    <count group_id="O2" value="986"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.735" lower_limit="1.285" upper_limit="2.370"/>
                    <measurement group_id="O2" value="1.700" lower_limit="1.220" upper_limit="2.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 16 Week 76)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="787"/>
                    <count group_id="O2" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.730" lower_limit="1.240" upper_limit="2.420"/>
                    <measurement group_id="O2" value="1.670" lower_limit="1.200" upper_limit="2.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 18 Week 100)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="554"/>
                    <count group_id="O2" value="561"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.755" lower_limit="1.260" upper_limit="2.420"/>
                    <measurement group_id="O2" value="1.610" lower_limit="1.240" upper_limit="2.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Visit on Treatment (LVT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="865"/>
                    <count group_id="O2" value="899"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.700" lower_limit="1.230" upper_limit="2.360"/>
                    <measurement group_id="O2" value="1.650" lower_limit="1.210" upper_limit="2.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="817"/>
                    <count group_id="O2" value="841"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.650" lower_limit="1.200" upper_limit="2.300"/>
                    <measurement group_id="O2" value="1.720" lower_limit="1.270" upper_limit="2.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin (Hb) A1c From Baseline Over Time Within and Between Treatment Groups</title>
        <time_frame>120 weeks</time_frame>
        <population>All subjects were analyzed and contributed HbA1c data for the 'High-Intensity Statin Therapy + RVX000222' and the 'High-Intensity statin therapy + Placebo' arms Subject data is missing across time points</population>
        <group_list>
          <group group_id="O1">
            <title>High-Intensity Statin Therapy+RVX000222</title>
            <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
          <group group_id="O2">
            <title>High-Intensity Statin Therapy+Placebo</title>
            <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin (Hb) A1c From Baseline Over Time Within and Between Treatment Groups</title>
          <population>All subjects were analyzed and contributed HbA1c data for the 'High-Intensity Statin Therapy + RVX000222' and the 'High-Intensity statin therapy + Placebo' arms Subject data is missing across time points</population>
          <units>% of hemoglobin</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1202"/>
                    <count group_id="O2" value="1195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.40" lower_limit="6.40" upper_limit="8.70"/>
                    <measurement group_id="O2" value="7.30" lower_limit="6.40" upper_limit="8.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Week 24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1058"/>
                    <count group_id="O2" value="1048"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.20" lower_limit="6.40" upper_limit="8.50"/>
                    <measurement group_id="O2" value="7.20" lower_limit="6.40" upper_limit="8.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1023"/>
                    <count group_id="O2" value="1037"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.30" lower_limit="6.40" upper_limit="8.60"/>
                    <measurement group_id="O2" value="7.30" lower_limit="6.40" upper_limit="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 16 (Week 76)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="808"/>
                    <count group_id="O2" value="833"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.30" lower_limit="6.50" upper_limit="8.65"/>
                    <measurement group_id="O2" value="7.40" lower_limit="6.50" upper_limit="8.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 18 (Week 100)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="575"/>
                    <count group_id="O2" value="576"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.30" lower_limit="6.40" upper_limit="8.70"/>
                    <measurement group_id="O2" value="7.30" lower_limit="6.50" upper_limit="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="900"/>
                    <count group_id="O2" value="933"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.40" lower_limit="6.40" upper_limit="8.90"/>
                    <measurement group_id="O2" value="7.30" lower_limit="6.40" upper_limit="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="858"/>
                    <count group_id="O2" value="874"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.30" lower_limit="6.40" upper_limit="8.70"/>
                    <measurement group_id="O2" value="7.20" lower_limit="6.40" upper_limit="8.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glucose From Baseline Over Time Between and Within Treatment Groups</title>
        <time_frame>120 weeks</time_frame>
        <population>All subjects were analyzed and contributed glucose data for the 'High-Intensity Statin Therapy + RVX000222' and the 'High-Intensity statin therapy + Placebo' arms.&#xD;
Subject data is missing across time points</population>
        <group_list>
          <group group_id="O1">
            <title>High-Intensity Statin Therapy+RVX000222</title>
            <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
          <group group_id="O2">
            <title>High-Intensity Statin Therapy+Placebo</title>
            <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glucose From Baseline Over Time Between and Within Treatment Groups</title>
          <population>All subjects were analyzed and contributed glucose data for the 'High-Intensity Statin Therapy + RVX000222' and the 'High-Intensity statin therapy + Placebo' arms.&#xD;
Subject data is missing across time points</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1210"/>
                    <count group_id="O2" value="1206"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.590" lower_limit="6.140" upper_limit="9.730"/>
                    <measurement group_id="O2" value="7.385" lower_limit="6.100" upper_limit="9.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Week 24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1068"/>
                    <count group_id="O2" value="1066"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.925" lower_limit="6.310" upper_limit="10.450"/>
                    <measurement group_id="O2" value="7.835" lower_limit="6.230" upper_limit="10.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1030"/>
                    <count group_id="O2" value="1044"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.900" lower_limit="6.290" upper_limit="10.390"/>
                    <measurement group_id="O2" value="7.800" lower_limit="6.420" upper_limit="10.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 16 (Week 76)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="826"/>
                    <count group_id="O2" value="844"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.920" lower_limit="6.390" upper_limit="10.340"/>
                    <measurement group_id="O2" value="7.840" lower_limit="6.250" upper_limit="10.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 18 (Week 100)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="580"/>
                    <count group_id="O2" value="586"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.010" lower_limit="6.365" upper_limit="10.535"/>
                    <measurement group_id="O2" value="7.890" lower_limit="6.280" upper_limit="10.670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="905"/>
                    <count group_id="O2" value="940"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.100" lower_limit="6.440" upper_limit="10.750"/>
                    <measurement group_id="O2" value="7.795" lower_limit="6.180" upper_limit="10.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="860"/>
                    <count group_id="O2" value="882"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.650" lower_limit="6.250" upper_limit="10.130"/>
                    <measurement group_id="O2" value="7.595" lower_limit="6.080" upper_limit="10.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Alkaline Phosphatase (ALP) From Baseline Over Time Within and Between Treatment Groups</title>
        <time_frame>172 weeks</time_frame>
        <population>Subject data is missing across time points</population>
        <group_list>
          <group group_id="O1">
            <title>High-Intensity Statin Therapy+RVX000222</title>
            <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
          <group group_id="O2">
            <title>High-Intensity Statin Therapy+Placebo</title>
            <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alkaline Phosphatase (ALP) From Baseline Over Time Within and Between Treatment Groups</title>
          <population>Subject data is missing across time points</population>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1212"/>
                    <count group_id="O2" value="1207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="64.0" upper_limit="95.5"/>
                    <measurement group_id="O2" value="77.0" lower_limit="64.0" upper_limit="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1156"/>
                    <count group_id="O2" value="1151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" lower_limit="58.0" upper_limit="88.0"/>
                    <measurement group_id="O2" value="76.0" lower_limit="62.0" upper_limit="91.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 4)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1136"/>
                    <count group_id="O2" value="1131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="58.0" upper_limit="88.0"/>
                    <measurement group_id="O2" value="75.0" lower_limit="63.0" upper_limit="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1102"/>
                    <count group_id="O2" value="1108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="56.0" upper_limit="87.0"/>
                    <measurement group_id="O2" value="75.0" lower_limit="61.0" upper_limit="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Week 8)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1125"/>
                    <count group_id="O2" value="1098"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" lower_limit="56.0" upper_limit="86.0"/>
                    <measurement group_id="O2" value="76.0" lower_limit="62.0" upper_limit="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (Week 10)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1100"/>
                    <count group_id="O2" value="1095"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" lower_limit="56.0" upper_limit="86.0"/>
                    <measurement group_id="O2" value="75.0" lower_limit="62.0" upper_limit="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1120"/>
                    <count group_id="O2" value="1109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" lower_limit="56.0" upper_limit="87.0"/>
                    <measurement group_id="O2" value="75.0" lower_limit="62.0" upper_limit="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1094"/>
                    <count group_id="O2" value="1095"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="55.0" upper_limit="85.0"/>
                    <measurement group_id="O2" value="75.0" lower_limit="61.0" upper_limit="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 10 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1091"/>
                    <count group_id="O2" value="1081"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="55.0" upper_limit="86.0"/>
                    <measurement group_id="O2" value="74.0" lower_limit="61.0" upper_limit="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Week 24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1082"/>
                    <count group_id="O2" value="1070"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="55.0" upper_limit="84.0"/>
                    <measurement group_id="O2" value="75.0" lower_limit="60.0" upper_limit="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12 (Week 28)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1073"/>
                    <count group_id="O2" value="1079"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" lower_limit="55.0" upper_limit="85.0"/>
                    <measurement group_id="O2" value="74.0" lower_limit="61.0" upper_limit="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 13 (Week 40)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1062"/>
                    <count group_id="O2" value="1068"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" lower_limit="56.0" upper_limit="87.0"/>
                    <measurement group_id="O2" value="74.0" lower_limit="61.0" upper_limit="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1035"/>
                    <count group_id="O2" value="1047"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" lower_limit="57.0" upper_limit="89.0"/>
                    <measurement group_id="O2" value="76.0" lower_limit="61.0" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 15 (Week 64)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="965"/>
                    <count group_id="O2" value="984"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" lower_limit="57.0" upper_limit="87.0"/>
                    <measurement group_id="O2" value="74.5" lower_limit="62.0" upper_limit="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 16 (Week 76)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="829"/>
                    <count group_id="O2" value="846"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="58.0" upper_limit="88.0"/>
                    <measurement group_id="O2" value="76.0" lower_limit="61.0" upper_limit="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 17 (Week 88)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="698"/>
                    <count group_id="O2" value="717"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" lower_limit="58.0" upper_limit="91.0"/>
                    <measurement group_id="O2" value="76.0" lower_limit="62.0" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 18 (Week 100)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="580"/>
                    <count group_id="O2" value="590"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" lower_limit="59.0" upper_limit="92.0"/>
                    <measurement group_id="O2" value="75.0" lower_limit="62.0" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 19 (Week 112)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="471"/>
                    <count group_id="O2" value="471"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" lower_limit="58.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="75.0" lower_limit="62.0" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 20 (Week 124)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="359"/>
                    <count group_id="O2" value="357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" lower_limit="57.0" upper_limit="92.0"/>
                    <measurement group_id="O2" value="77.0" lower_limit="63.0" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 21 (Week 136)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5" lower_limit="56.0" upper_limit="92.0"/>
                    <measurement group_id="O2" value="77.0" lower_limit="62.0" upper_limit="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 22 (Week 148)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" lower_limit="56.0" upper_limit="88.0"/>
                    <measurement group_id="O2" value="76.0" lower_limit="64.0" upper_limit="91.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 23 (Week 160)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="57.5" upper_limit="87.5"/>
                    <measurement group_id="O2" value="78.0" lower_limit="55.0" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 24 (Week 172)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" lower_limit="62.0" upper_limit="89.0"/>
                    <measurement group_id="O2" value="83.0" lower_limit="64.0" upper_limit="112.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Visit on Treatment (LVT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="906"/>
                    <count group_id="O2" value="940"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" lower_limit="59.0" upper_limit="91.0"/>
                    <measurement group_id="O2" value="77.0" lower_limit="62.0" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="860"/>
                    <count group_id="O2" value="882"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" lower_limit="63.0" upper_limit="93.0"/>
                    <measurement group_id="O2" value="76.0" lower_limit="62.0" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C Reactive Protein (CRP) Concentration From Baseline Over Time Within and Between Treatment Groups</title>
        <time_frame>52 weeks</time_frame>
        <population>A select subset of subjects in two countries were analyzed for CRP, Subject data is missing across time points.</population>
        <group_list>
          <group group_id="O1">
            <title>High-Intensity Statin Therapy+RVX000222</title>
            <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
          <group group_id="O2">
            <title>High-Intensity Statin Therapy+Placebo</title>
            <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C Reactive Protein (CRP) Concentration From Baseline Over Time Within and Between Treatment Groups</title>
          <population>A select subset of subjects in two countries were analyzed for CRP, Subject data is missing across time points.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="239"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.875" lower_limit="1.245" upper_limit="5.915"/>
                    <measurement group_id="O2" value="2.740" lower_limit="1.130" upper_limit="6.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="224"/>
                    <count group_id="O2" value="218"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.755" lower_limit="0.875" upper_limit="3.895"/>
                    <measurement group_id="O2" value="1.805" lower_limit="1.000" upper_limit="4.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.710" lower_limit="0.860" upper_limit="4.050"/>
                    <measurement group_id="O2" value="1.580" lower_limit="0.720" upper_limit="3.710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline Over Time Within and Between Treatment Groups for Subjects With Impaired Renal Function at Baseline (eGFR &lt;60 mL/Min/1.7m2)</title>
        <time_frame>120 weeks</time_frame>
        <population>Subject data is missing across time points</population>
        <group_list>
          <group group_id="O1">
            <title>High-Intensity Statin Therapy+RVX000222</title>
            <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
          <group group_id="O2">
            <title>High-Intensity Statin Therapy+Placebo</title>
            <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline Over Time Within and Between Treatment Groups for Subjects With Impaired Renal Function at Baseline (eGFR &lt;60 mL/Min/1.7m2)</title>
          <population>Subject data is missing across time points</population>
          <units>ml/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" lower_limit="41.4" upper_limit="56.0"/>
                    <measurement group_id="O2" value="48.9" lower_limit="40.6" upper_limit="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Week 24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="106"/>
                    <count group_id="O2" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0" lower_limit="41.5" upper_limit="63.7"/>
                    <measurement group_id="O2" value="53.3" lower_limit="41.4" upper_limit="63.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="41.3" upper_limit="62.2"/>
                    <measurement group_id="O2" value="52.5" lower_limit="41.8" upper_limit="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 16 (Week 76)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" lower_limit="37.5" upper_limit="63.6"/>
                    <measurement group_id="O2" value="54.8" lower_limit="42.5" upper_limit="63.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 18 (Week 100)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" lower_limit="34.0" upper_limit="59.3"/>
                    <measurement group_id="O2" value="56.7" lower_limit="42.4" upper_limit="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" lower_limit="39.2" upper_limit="62.3"/>
                    <measurement group_id="O2" value="53.9" lower_limit="43.3" upper_limit="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Incidence of First Occurrence of Adjudication-Confirmed Four-Point MACE</title>
        <description>First occurrence of four-point MACE defined as a single composite endpoint of cardiovascular (CV) death (including undetermined cause of death) or non-fatal myocardial infarction (MI), stroke or hospital admission for congestive heart failure.</description>
        <time_frame>120 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-Intensity Statin Therapy+RVX000222</title>
            <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
          <group group_id="O2">
            <title>High-Intensity Statin Therapy+Placebo</title>
            <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of First Occurrence of Adjudication-Confirmed Four-Point MACE</title>
          <description>First occurrence of four-point MACE defined as a single composite endpoint of cardiovascular (CV) death (including undetermined cause of death) or non-fatal myocardial infarction (MI), stroke or hospital admission for congestive heart failure.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CV Death (CVD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-fatal MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Hospitalization for CHF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Log Rank</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>120 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High-Intensity Statin Therapy+RVX000222</title>
          <description>Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Apabetalone: 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
        </group>
        <group group_id="E2">
          <title>High-Intensity Statin Therapy+Placebo</title>
          <description>Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)&#xD;
Placebo: Capsule manufactured to mimic RVX000222 100 mg capsule&#xD;
Atorvastatin: High-Intensity Statin&#xD;
Rosuvastatin: High-Intensity Statin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="354" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="339" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Anginal equivalent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cardiac discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Microvascular coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Myocardial fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Detachment of retinal pigment epithelium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hypotony of eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Iris bombe</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Haemorrhoids thrombosed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Oesophageal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Vascular stent restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Exercise tolerance decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Vascular stent occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Vascular stent stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Vascular stent thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyloidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Ertsipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Acute endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Opportunistic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Lumbosacral plexus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Nerve root injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Postpericardiotomy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Radial head dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Blood pressure abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Metabolic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Ankylosing spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Benign hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of unknown primary site</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Nasopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Oropharyngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Ovarian cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Ovarian fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Paraneoplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Small cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Uterine neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Quadriparesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Carotid sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cervical cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Lumbosacral radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Bladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Ureteric rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Bronchial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Paranasal sinus haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Sinus polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Tracheal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Vocal cord cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Subclavian artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="830" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="820" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Hepatobiliary</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT increase</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="1207"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="1207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. Director of Clinical Operations</name_or_title>
      <organization>Resverlogix Corp.</organization>
      <phone>403.254.9252</phone>
      <email>clinicaltrials@resverlogix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

